Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and ...
Revolution Medicines' daraxonrasib is the first drug that can broadly tackle one of the main drivers of pancreatic cancer.
Researchers are asking why patients, like former Senator Ben Sasse, inevitably develop resistance to the drug daraxonrasib.
When an ad for a new cancer drug pops up in your newsfeed, it might look like an overnight success. But even developing a ...
The FDA’s approval of daraxonrasib marks a significant development in pancreatic cancer treatment, with clinical trial ...
The U.S. FDA has approved Revolution Medicines’ groundbreaking pancreatic cancer drug after it was shown to double the survival rate of patients with advanced disease in a large trial, offering new ...
Baller Alert on MSN
FDA greenlights groundbreaking breast cancer treatment, and the new pill targets a mutation that can make cancer drugs stop working
The FDA has cleared a new breast cancer treatment strategy that does not wait for a scan to show the disease getting worse.
Daraxonrasib (Rasonque), recently approved for the treatment of metastatic pancreatic cancer, is also showing promise in the treatment of lung cancer in early trials.
Oct 1 (Reuters) - Foghorn Therapeutics said on Thursday it has discontinued development of an experimental cancer drug partnered with Eli Lilly after it failed to show enough benefit in an early-stage ...
How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages Northwestern University economist ...
Merck said on Monday it would pay up to $2.13 billion under a global licensing deal with China's SciBrunch Therapeutics for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results